Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | RAB9A | P51151 | 1/20 | 0.74 |
| ▸ | ROCK2 | O75116 | 13/20 | 0.46 |
| ▸ | GRK2 | P25098 | 12/20 | 0.46 |
| ▸ | GRK3 | P35626 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 2/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16153996 | 0.85 | RAB9A (1.00) | LMNARAB9AHSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL4789113 | 0.80 | ROCK2 (0.55) | LMNARAB9AROCK2GRK2GRK3 | |
| SCHEMBL6037006 | 0.79 | ROCK2 (0.54) | LMNARAB9AROCK2GRK2GRK3 | |
| SCHEMBL22950517 | 0.77 | RAB9A (0.71) | LMNARAB9AHSD17B10HPGD | |
| SCHEMBL22949632 | 0.74 | RAB9A (0.65) | LMNARAB9AHSD17B10HPGD | |
| SCHEMBL4788582 | 0.73 | ROCK2 (0.62) | ROCK2GRK2GRK3PRKCA | |
| SCHEMBL22950631 | 0.72 | LMNA (0.57) | LMNARAB9AHSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL873891 | 0.72 | LMNA (0.57) | LMNARAB9AHSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL4790463 | 0.71 | ROCK2 (0.58) | LMNAROCK2GRK2GRK3PRKCA | |
| SCHEMBL304656 | 0.71 | CYP19A1 (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008011557-A2 | HETEROARYL INHIBITORS OF RHO KINASE | BORCHARDT ALLEN J (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011557-A2 | HETEROARYL INHIBITORS OF RHO KINASE | BORCHARDT ALLEN J (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | Borchardt, Allen (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | Borchardt, Allen (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | Borchardt, Allen (US) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | ROCK1, ROCK2, RHOA | LMNA 1847/4885RAB9A 232/4885ROCK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.